Paridaens Henry, Gruson Damien
Département des laboratoires cliniques, Cliniques universitaires Saint-Luc et Université catholique de Louvain, Bruxelles, Belgique.
Département des laboratoires cliniques, Cliniques universitaires Saint-Luc et Université catholique de Louvain, Bruxelles, Belgique, Pôle de recherche en endocrinologie, diabète et nutrition, Institut de recherche expérimentale et clinique, Cliniques universitaires Saint-Luc et Université catholique de Louvain, Bruxelles, Belgique.
Ann Biol Clin (Paris). 2017 Jun 1;75(3):245-258. doi: 10.1684/abc.2017.1240.
Preeclampsia which affects approximatively 2% of pregnancies is a major cause of maternal and perinatal morbidity and mortality. Pathogenesis of pre-eclampsia is nowadays increasingly understood. It implies multiple actors and biomarkers appear to be playing a major role. New uses of those biomarkers for risk stratification and diagnosis of predisposed preeclamptic patients followed by obstetricians is an hot topic. The combined approach of biomarkers, medical history and obstetrical ultrasounds enables risk estimation in the first quarter and later on. A better understanding of this risk would enable better monitoring of obstetrical patients and reduce the occurrence of adverse complications for them and for the fetal well-being.
子痫前期影响约2%的妊娠，是孕产妇和围产期发病和死亡的主要原因。如今，子痫前期的发病机制越来越为人所理解。它涉及多个因素，生物标志物似乎起着重要作用。产科医生对这些生物标志物在易患子痫前期患者的风险分层和诊断中的新应用是一个热门话题。生物标志物、病史和产科超声的综合方法能够在孕早期及之后进行风险评估。更好地理解这种风险将有助于更好地监测产科患者，并减少对她们及胎儿健康产生的不良并发症的发生。
